

ADHD – Stimulant Agents

| Override(s) | Approval Duration |
|---------------------------------------|-------------------|
| Prior Authorization Quantity Limit | 1 year |

| Quantity Limit | |
|----------------|----------------------------------|
| All agents | May be subject to quantity limit |

| Medications | Comments |
|--|---------------|
| <p><u>Dexmethylphenidate:</u> Focalin generic Focalin XR generic</p> | Preferred |
| <p><u>Dextroamphetamine and Amphetamine:</u> Adderall generic Adderall XR generic[‡]</p> | |
| <p><u>Dextroamphetamine:</u> Dextroamphetamine 5mg, 10mg tablets generic Dexedrine capsules generic</p> | |
| <p><u>Methylphenidate:</u> Metadate ER generic methylphenidate products, except: chewable tablets</p> | |
| <p><u>Amphetamine:</u> Dyanavel XR suspension, tablets Adzenys XR-ODT Evekeo tablets</p> | Non-Preferred |
| <p><u>Dextroamphetamine and Amphetamine:</u> Adderall Brand Adderall XR Brand[‡] Mydayis ER</p> | |
| <p><u>Dextroamphetamine:</u> Dexedrine spansules Brand ProCentra solution (and generic) Zenedi Dextroamphetamine tablets 2.5mg, 7.5mg, 15mg, 20mg, 30mg tablets generic</p> | |

| | |
|---|---------------------------|
| <u>Dexmethylphenidate:</u> Focalin Brand Focalin XR Brand | Non-Preferred (continued) |
| <u>Transdermal Dextroamphetamine:</u> Xelstrym | |
| <u>Methamphetamine:</u> Desoxyn (and generic) | |
| <u>Methylphenidate:</u> Aptensio XR (and generic) Concerta Brand Cotempla XR – ODT Jornay PM Metadate CD Brand Methylin Solution Methylphenidate chewable tablets Relexxii ER Ritalin Brand Ritalin LA Brand Quillichew ER Brand Quillivant XR Brand | |
| <u>Transdermal Methylphenidate:</u> Daytrana | |
| <u>Serdexmethylphenidate and Dexmethylphenidate:</u> Azstarys | |

‡Requests for quantities greater than 30 mg per day in individuals 13 years of age or older will be reviewed for medical necessity (AHFS, DrugPoints).

Attention deficit hyperactivity disorder (ADHD) may also be referred to as attention deficit disorder (ADD).

Individuals age 19 and over will require prior authorization for diagnosis and trial of preferred products where applicable.

STEP THERAPY APPROVAL CRITERIA:

Requests for a non-preferred, stimulant ADHD agent [Azstarys, Dyanavel XR (suspension, tablets), Adenzys XR-ODT, Adderall (brand), Adderall XR (brand), Mydayis ER, Desoxyn, Dexedrine Spansules (brand), dextroamphetamine (generic) 15mg, 20mg, 30mg tablets, Evekeo/Evekeo ODT, Focalin (brand), Focalin XR (brand), Daytrana, Procentra solution (and generic), Zenedi (brand), Aptensio XR (brand and generic), Concerta (brand), Cotempla XR-ODT, Jornay PM, Metadate CD (brand), Methylin Solution, methylphenidate chewable tablets, Ritalin (brand), Ritalin LA (brand), Quillichew ER, Quillivant XR, Relexxii ER tablets (brand), Xelstrym] may be approved if the following step therapy criteria are met **in addition to** any prior

authorization criteria listed below:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to one preferred stimulant agent;

Preferred agents: dexamethylphenidate (IR and XR), dextroamphetamine-amphetamine tablet (IR and ER), dextroamphetamine 5mg, 10mg tablets, dextroamphetamine SR capsules, the following generic methylphenidate agents: [methylphenidate ER/SR/CR tablet, methylphenidate tablet/oral solution, methylphenidate ER 24-hr tablet (AB-rated generic Concerta), methylphenidate CD/ER/LA capsule], Metadate ER.

PRIOR AUTHORIZATION APPROVAL CRITERIA:

- I. Requests for dexamethylphenidate (Focalin and generic, Focalin XR and generic), amphetamine [Dyanavel XR (suspension, tablets), Adzenys XR-ODT], and serdexmethylphenidate/dexamethylphenidate (Azstarys) may be approved if the following criteria are met:

- A. Individual is 6 years of age or older; **AND**
- B. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD).

Requests for amphetamine [Dyanavel XR (tablets, suspension), Adzenys XR-ODT], Serdexmethylphenidate and Dexmethylphenidate (Azstarys), and dexamethylphenidate (Focalin and Focalin XR) agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems; **OR**
- B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

- II. Requests for amphetamine sulfate tablets (Evekeo) may be approved when the following criteria are met:

- A. Individual is 3 years of age or older; **AND**
- B. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD);

OR

- C. Individual is 6 years of age or older; **AND**
- D. Individual has a diagnosis of narcolepsy.

Requests for amphetamine sulfate tablets (Evekeo) may not be approved in the presence of the following diagnoses:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems; **OR**

- B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

IV. Requests for methamphetamine (Desoxyn) may be approved if following criteria are met:

- A. Individual is 6 years of age or older; **AND**
- B. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD).

Requests for Desoxyn (methamphetamine) may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, or other serious heart problems; **OR**
- B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

III. Requests for transdermal methylphenidate (Daytrana) may be approved if the following criteria are met:

- A. Individual is 6 years of age or older; **AND**
- B. Individual has a diagnosis of attention deficit hyperactivity disorder; **AND**
- C. Individual has had a suboptimal response to **one** maximally titrated long-acting methylphenidate product; **OR**
- D. Individual has experienced **one** of the following adverse effects on previous therapy:
 - 1. Diminished appetite and documented weight loss from baseline over a three (3) month observation period; **OR**
 - 2. An elevated blood pressure over baseline demonstrated by at least three measurements over one (1) week period; **OR**
 - 3. Behavior or mood changes interfering with daily activities, including complaints of abdominal distress, sleep problems, or oppositional/rebellious/aggressive behavior.

Requests for transdermal methylphenidate (Daytrana) agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems; **OR**
- B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

IV. Requests for dextroamphetamine [Dexedrine, Dexedrine Spansules, ProCentra solution (and generic), Zenzedi and generic products] may be approved if the following criteria are met:

- A. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**
- B. One of the following:
 - 1. Individual is 3 years of age or older and using immediate-release product;**OR**

2. Individual is 6 years of age or older and using an extended-release product;

OR

C. Individual is 6 years of age or older; **AND**

D. Individual has a diagnosis of narcolepsy.

Requests for dextroamphetamine (Dexedrine, Dexedrine Spansules, ProCentra, Zenzedi) agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems; **OR**
 - B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.
- V. Requests for transdermal dextroamphetamine (Xelstrym) may be approved if the following criteria are met:
 - A. Individual is 6 years of age or older; **AND**
 - B. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD).

Requests for transdermal dextroamphetamine (Xelstrym) agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems; **OR**
 - B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.
- VI. Requests for dextroamphetamine/amphetamine salt combination (Adderall, Adderall XR and generic products) agents may be approved if the following criteria are met:
 - A. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**
 - B. One of the following:
 - 1. Individual is 3 years of age or older and using an immediate-release product;**OR**
 - 2. Individual is 6 years of age or older and using an extended-release product;**OR**
 - C. Individual is 6 years of age or older; **AND**
 - D. Individual is using an immediate-release product for the treatment of narcolepsy.

Requests for amphetamine/dextroamphetamine salt combination (Adderall, Adderall XR) agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems; **OR**
- B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

- VII. Requests for dextroamphetamine/amphetamine salt combination (Mydayis ER products) agents may be approved if the following criteria are met:
- A. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**
 - B. Individual is 13 years of age or older.

Requests for amphetamine/dextroamphetamine salt combination (Mydayis ER) agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, or other serious heart problems; **OR**
- B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

- VIII. Requests for methylphenidate (Methylin Solution, Ritalin, and generic products) may be approved if the following criteria are met:

- A. Individual is 6 years of age or older; **AND**
- B. One of the following:
 - 1. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **OR**
 - 2. Individual has a diagnosis of narcolepsy.

OR

- C. Individual is 4 or 5 years of age; **AND**
- D. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**
- E. Individual and caregivers have participated in behavioral interventions; **AND**
- F. Individual continues with moderate-to-severe disturbance in function. (AAP 2019).

- IX. Requests for methylphenidate [Aptensio XR, Cotempla XR-ODT, Concerta, Jornay PM, Metadate CD, Metadate ER, Relexxii ER tablets, Quillichew ER, Quillivant XR, Ritalin LA, and generic products] may be approved if the following criteria are met:

- A. Individual is 6 years of age or older; **AND**
- B. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD);

OR

- C. Individual is 4 or 5 years of age (excluding Aptensio XR); **AND**
- D. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**
- E. Individual and caregivers have participated in behavioral interventions; **AND**
- F. Individual continues with moderate-to-severe disturbance in function. (AAP 2019)

Requests for oral methylphenidate agents may not be approved for the following:

- A. Individual has known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, or other serious heart problems; **OR**

B. Individual is currently using a monoamine oxidase inhibitor (MAOI) or has used an MAOI in the previous 14 days.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 3, 2025.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; Updated periodically.
4. American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2019;144(4):e20192528. Available at: <https://pediatrics.aappublications.org/content/pediatrics/144/4/e20192528.full.pdf> Accessed: July 3, 2025.
5. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. MME2202 290-02-0020.) AHRQ Publication No. 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2011. Last Review July 2012. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
6. Olagunju AE, Ghoddsi F. Attention-Deficit/Hyperactivity Disorder in Adults. *Am Fam Physician*. 2024;110(2):157-166. Available from: file:///C:/Users/AF38863/Downloads/Olagunju%202024_ADHD%20in%20adults.pdf. Accessed July 3, 2025.
7. Post RE and Kurlansik SL. Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults. *Am Fam Physician*. 2012; 85(9):890-896. Available from: <http://www.aafp.org/afp/2012/0501/p890.html>. Accessed June 24, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.